You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
|
|---|---|
| Published in |
American Journal of Kidney Diseases, August 2014
|
| DOI | 10.1053/j.ajkd.2014.06.020 |
| Pubmed ID | |
| Authors |
David W. Johnson, Elaine M. Pascoe, Sunil V. Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P. McDonald, Alicia T. Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A. Vergara, Carmel M. Hawley, HERO Study Collaborative Group |
| Abstract |
Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 1% |
| Slovenia | 1 | 1% |
| Unknown | 84 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 10% |
| Other | 8 | 9% |
| Researcher | 8 | 9% |
| Student > Postgraduate | 8 | 9% |
| Student > Master | 8 | 9% |
| Other | 21 | 24% |
| Unknown | 24 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 35% |
| Nursing and Health Professions | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Economics, Econometrics and Finance | 3 | 3% |
| Other | 15 | 17% |
| Unknown | 24 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2018.
All research outputs
#8,261,756
of 25,373,627 outputs
Outputs from American Journal of Kidney Diseases
#3,301
of 5,427 outputs
Outputs of similar age
#75,960
of 242,444 outputs
Outputs of similar age from American Journal of Kidney Diseases
#35
of 51 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 5,427 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.9. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,444 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.